Robotaxi maker Pony.ai sees Trump's trade war hitting sentiment, overseas expansion plans
China-based
robotaxi
developer
Pony.ai
Inc said on Thursday that U.S. President Donald Trump's trade war with China was likely to dampen its international expansion plans, but it anticipated little direct impact on its supply chain.
The Toyota-backed company has been exploring the deployment of its
autonomous driving
business in South Korea, Luxembourg, the Middle East and other countries after raising $260 million from listing on the Nasdaq in November.
Trump's move to impose a blanket 10per cent tariff on all other U.S. imports and a higher 145per cent levies on Chinese products has roiled markets and forced companies to reassess plans. On Thursday, however, the Trump administration signalled an openness to de-escalating the trade war with China.
Asked about the tariffs, Pony.Ai's CEO James Peng said on the sidelines of the Shanghai auto show that his company did not foresee a direct impact.
"On the supply side, we always try to have alternatives and backups," he told Reuters. "But I think sentimentally of course this is going to affect us, especially on our plan for international expansion."
The company uses Nvidia's autonomous-grade Orin-X chips and would likely go on to use its newer Drive Thor chips that are not restricted from being sold in China, Peng said.
"It's very hard to imagine those chips will be on restriction. Alternatively of course, we also have some backup suppliers from the Chinese domestic chip manufacturers," he said.
Founded in Silicon Valley in 2016, Pony.ai has research centres in China, the United States and Luxembourg.
Asked about whether the company might explore a secondary listing in Hong Kong, Peng said it was a potential option but that its focus was on starting production of its 7th generation of vehicles. Pony.ai currently has robotaxi service licences in Beijing, Shanghai, Guangzhou and Shenzhen and is seeking to launch the services in Hong Kong.
"Currently all the assembly line has been modified for the mass production. Our target is that for this year we'll reach close to 1,000 vehicles," he said.
"For the next few years, we're going to actually very rapidly expand the offering and mass production once we have the assembly line all tooled up. I think now is the matter of the demand. We definitely are going to go beyond tens of thousands very soon."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
16 minutes ago
- Mint
Trump wants cheaper drugs like Europe has. How it works.
President Donald Trump doesn't just want to bring down prescription drug prices for Americans. He wants European countries to raise them to make up the revenue that drugmakers would lose from his policy. Trump is proposing a so-called most-favored-nation pricing model, which would set U.S. drug prices at the lowest level in other wealthy countries. But the pharmaceutical industry isn't buying into tying drug prices in the U.S. to prices in Europe—at least not knowing the details of the president's proposal. More details about the government's pricing model could come this week. On May 12, Trump directed government health officials to benchmark drug prices to international standards within 30 days. The lobbying group PhRMA, with members including U.S. pharma giants Eli Lilly, Pfizer, Johnson & Johnson, and AbbVie, has argued there are two reasons why U.S. drug prices are high: foreign countries not paying 'their fair share" for medicines, and middlemen such as pharmacy-benefit managers. Today, U.S. drug pricing is largely market driven. It involves negotiations between drug manufacturers, pharmacy-benefit managers, healthcare insurers and providers. European countries do it much differently. Each has its own way of determining drug prices, but most follow one of two broad approaches. The first approach, which Germany and France use, considers the overall clinical effectiveness of a new medicine. How does the new treatment compare to existing ones? Does it have added therapeutic benefits? If the new drug is substantially better, its price would reflect that. A second approach, used by the U.K., the Netherlands, and Sweden, analyzes cost effectiveness. This model not only compares the new drug to existing ones but also assesses the incremental value that the medicine brings to the health system. After the assessments, negotiations between drugmakers and the countries begin. Because many European countries have national health systems, they are in a strong negotiation position. If government negotiators think a medicine is too expensive for its effectiveness, they won't recommend its use. How Trump's MFN policy would work in practice isn't clear. Drug prices would probably be based on list prices in Europe since the prices paid by national health systems, or net prices, are confidential. The president's open-ended directive, laid out in an executive order, has many wondering how the U.S. could raise prices in Europe. Trump has made clear he wants to close the gap between U.S. and international prices, and has suggested he would use tariffs and export controls to achieve his goal. In theory, drugmakers could set list prices higher in Europe as long as it doesn't affect net prices, health policy expert Dr. Huseyin Naci told Barron's. In the U.K., for example, a higher list price could still lower the prices in other European countries. 'So that would still not be an acceptable approach to many other European countries," said Naci, who is associate professor of health policy at the London School of Economics. Overhauling Europe's decades-old pricing approaches would require fundamental changes to their pricing regulations—and there will be 'little appetite or ability" to alter them, Naci added. Cost is another complicating factor. 'Pharmaceutical spending is already one of the top categories of spending in many countries in terms of healthcare expenditure, so there's little room to accommodate higher prices and spending for pharmaceuticals in Europe," according to Naci. How Trump is planning to make Europeans pay more for drugs is the big question. He could use tariffs and trade negotiations as leverage. In early April, the president said a 'major" tax on pharmaceutical imports is coming 'very shortly," however nothing has been announced yet. In a trade agreement with the U.K. a month later, there is a provision on pharmaceuticals that states the U.K. will 'endeavor to improve the overall environment for pharmaceutical companies." What that means in practice still isn't clear. Write to Elsa Ohlen at
Economic Times
17 minutes ago
- Economic Times
Lumpsum vs SIP: Is caution killing the case for lumpsum?
Mutual fund SIP inflows hit record highs in May amid market rally. Investors are cautious about lumpsum investments due to geopolitical tensions and slowdown fears. Vishal Dhawan suggests hybrid equity funds for lumpsum investments. Equity mutual fund inflows dropped, while hybrid funds saw increased interest. Overall mutual fund inflows decreased, but total assets under management grew. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads With mutual fund SIP inflows reaching record highs in May amid a market rally, a key question arises: Why are investors moving away from lumpsum investments? An expert explains that geopolitical tensions, trade concerns, and fears of a global slowdown—along with muted earnings and valuation worries—have made investors more cautious about lumpsum investing.'A combination of geopolitical uncertainty, trade wars, and fears of a global slowdown have made investors less confident about investing in lumpsums and more inclined towards SIPs in the current environment. Additionally, the slowdown in corporate earnings and concerns over the valuations of mid- and small-cap stocks are pushing investors to prefer SIPs as their investment strategy,' said Vishal Dhawan, CEO of Plan Ahead Wealth Advisors, a Mumbai-based wealth management firm, in a conversation with May, mutual fund SIP inflows rose marginally by 0.21% to Rs 26,688 crore, compared to Rs 26,632 crore in April. On a yearly basis, SIP inflows have surged nearly 28% from Rs 20,904 crore in May the current financial year so far, total SIP contributions by investors stand at approximately Rs 53,320 crore. For the calendar year to date, total SIP contributions have reached nearly Rs 1.31 lakh crore, up from Rs 98,571 crore during the same period last benchmark indices—Nifty50 and BSE Sensex—are down about 4% from their 52-week highs. With markets hovering near record levels, is the fear of buying at the peak discouraging lumpsum investments?Addressing the trend, Dhawan noted that investors often anchor to index highs, and their past experience of corrections from those levels tends to impact their willingness to invest in to the latest monthly data from the Association of Mutual Funds in India ( AMFI ), equity mutual funds witnessed a 22% drop in monthly inflows, receiving Rs 19,013 crore in May compared to Rs 24,269 crore in mutual funds saw an outflow of Rs 15,908 crore in May, a sharp reversal from the inflow of Rs 2.19 lakh crore in April. Meanwhile, hybrid mutual funds attracted higher inflows than equity mutual funds in May, with inflows rising 46% to Rs 20,765 crore from Rs 14,247 crore in funds saw a steep 73% decline in monthly inflows, receiving Rs 5,525 crore in May compared to Rs 20,229 crore in April. Different mutual fund categories showed mixed trends, with some attracting investor interest while others witnessed a advises that investors can still consider lumpsum investments in the current environment through hybrid equity funds, multi-asset funds, balanced advantage funds, and equity savings mutual fund inflows dropped by 89% in May. However, total assets under management (AUM) grew 3%, rising to Rs 71.93 lakh crore in May from Rs 69.73 lakh crore in April.
&w=3840&q=100)
Business Standard
18 minutes ago
- Business Standard
No disruption in operations due to rare earth supply crisis: Maruti
Automaker says situation is 'uncertain and evolving' amid report that it has made e-Vitara production cuts Deepak Patel New Delhi Maruti Suzuki India (MSIL) said on Thursday its operations are unaffected by the global rare earth magnet shortage, but added that the situation is 'uncertain and evolving'. The company said it is exploring multiple solutions to maintain continuity in operations and will notify stakeholders if any material impact arises. The clarification comes amid a Reuters report earlier this week stating that the country's largest carmaker has slashed production estimates for its upcoming electric SUV, the e-Vitara, by nearly two-thirds due to rare earth supply constraints. According to the report, MSIL has revised its production target for the e-Vitara from 26,000 units to just 8,200 units for the first half of FY26. The report, citing internal documents, attributed the change to 'supply constraints' of critical rare earth elements, particularly magnets used in electric powertrains. Despite the scale back, MSIL reportedly aims to meet its full-year target of 67,000 units by ramping up production in the second half of the financial year. 'Regarding the situation on rare earth, as of now there is no disruption in our operation due to this issue,' said a MSIL spokesperson, in a statement on Thursday. 'There is a lot of uncertainty and the situation is continuously evolving. We are monitoring the situation and pursuing multiple solutions to ensure continuity in our operations. If and when there is any material impact to our business, we will inform all stakeholders in line with regulatory requirements,' the spokesperson added. Rare earth magnets are a crucial component in electric vehicle (EV) motors and are also used in power steering systems, speakers, and other car components. Their shortage stems from China's decision in April to tighten export controls on key rare earth elements, including neodymium, dysprosium and terbium. These elements are essential in the production of permanent magnets used in EVs. According to the Federation of Automobile Dealers Associations (FADA), electric car sales in India reached 107,645 units in fiscal year 2024–25, up from 91,506 units in FY24, marking a 17.7 per cent year-over-year increase. China controls more than 90 per cent of the global rare earth magnet supply chain. China's new export rules require companies to obtain end-use certifications and licences, which has slowed shipments and created uncertainty for automakers worldwide. The disruption has raised alarm in India's automotive industry, especially among EV manufacturers who depend heavily on Chinese supplies. The Indian government is monitoring the situation. A delegation may soon travel to China to expedite clearances for shipments stuck due to regulatory bottlenecks. Additionally, the government is evaluating measures such as incentivising domestic rare earth magnet production and expanding recycling initiatives. The rare earth crunch comes at a time when Indian automakers are stepping up EV production to meet future emission targets and global demand.
